Articles tagged with Alzheimer Disease
Researchers from the NIDCD presented studies on the effects of chronic inflammation on taste tissues in the tongue, as well as the neural mechanisms underlying the anticipation of flavors. Their findings offer new insights into the progression of olfactory dysfunction in Alzheimer's disease and potential strategies for treatment.
A study found that higher levels of the protein clusterin in blood are associated with increased prevalence and severity of Alzheimer's disease. However, clusterin levels do not predict the development of new AD cases or all-cause dementia.
A new technique allows scientists to observe herpes simplex virus type 1 (HSV1) infections growing inside cells, revealing a mechanism by which HSV1 leads to Alzheimer's disease. Frequent interactions between viral particles and cellular amyloid precursor protein facilitate viral transport while interfering with normal APP distribution.
A consortium of researchers has identified four new genes associated with an increased risk of developing Alzheimer's disease. The study analyzed over 54,000 individuals and found that these genes contribute to the disease by disrupting brain biochemistry. Understanding the role of these genes could lead to the development of new treat...
A large-scale study identified four new genes linked to Alzheimer's disease, adding to the existing pool of genes that contribute to the risk. The findings provide valuable insights into the disease's underlying mechanisms and may lead to the development of more effective treatments and preventive measures.
Researchers identified four new genes, MS4A, CD2AP, CD33, and EPHA1, linked to Alzheimer's disease risk, adding to the understanding of the disease's causes. The findings may help determine who is at risk and aid in drug development.
Researchers have uncovered five new genes that increase the risk of developing Alzheimer's disease, adding to a total of ten identified genes. The study found that these genes are clustered in patterns, implicating immune system and cholesterol processing as risk factors.
Researchers have identified four new genes linked to Alzheimer's disease, adding to the existing understanding of its causes. The findings, published in Nature Genetics, provide key information for developing treatments and preventive measures.
A low-dose insulin treatment has been found to suppress the expression of four precursor proteins involved in Alzheimer's disease pathogenesis. Insulin also showed anti-inflammatory effects on peripheral mononuclear cells, which may lead to a new therapeutic agent for Alzheimer's disease.
A new biomarker for tau-related brain disorders has been identified, suggesting a potential target for drug discovery and biomarker development. Acetylation may play a role in faulty binding of tau to microtubules, contributing to neurodegeneration in Alzheimer's disease.
A study published in Nature reveals that Basic Yellow 1, a neurodegenerative marker, also has anti-aging properties in nematode worms. The compound extends lifespan by more than 50% and slows disease-like pathology in healthy worms.
A study found that individuals with amyloid plaques and no cognitive impairment exhibited similar brain structure changes to those with Alzheimer's disease. The researchers aim to identify potential therapeutic targets to prevent the development of dementia.
A study published in Nature Chemical Biology reveals that mutations in the p53 protein lead to protein aggregation, disrupting its protective function. This causes uncontrolled cell growth and tumor formation, highlighting a new mechanism for cancer development.
Researchers at Mount Sinai School of Medicine found that patients with Alzheimer's disease have lower glucose utilization in the brain, detectable approximately 20 years prior to symptoms. The study suggests that novel therapies could prevent the onset of Alzheimer's by addressing mitochondrial impairment.
Researchers found that Zileuton, an asthma drug, reduced gamma secretase's production of amyloid beta and subsequent plaque buildup in the brain by over 50% in a transgenic mouse model. This breakthrough suggests potential for new Alzheimer's treatment using an FDA-approved medication.
Researchers found that brain plasticity, the brain's ability to change and reorganize itself, can be improved in elderly subjects with mild cognitive impairment (MCI) through a simple memory training program. This increases correct answers by 33% and opens new avenues for research into slowing Alzheimer's disease progression.
The Harry T. Mangurian, Jr., Foundation has awarded Mayo Clinic a $1 million gift to understand how Lewy body dementia develops, how to treat it more effectively, and how to diagnose it earlier. Researchers will use genetics, new drugs, and imaging techniques to advance knowledge about the disorder.
Researchers at Duke University Medical Center have found a cascade of signaling molecules that allow brief signals to last for tens of minutes, forming stronger connections in the brain. This discovery could lead to new insights into diseases like Alzheimer's and autism.
Researchers at UCLA have discovered a potential biomarker to track Alzheimer's disease progression and treatment effectiveness. The study found that the immune gene MGAT3 is expressed differently in various patient groups, which may lead to personalized disease prognoses and therapy responses.
Researchers identify SMER28 molecule that increases autophagy to clear amyloid-beta protein aggregates. Increasing autophagy may improve treatment outcomes for neurodegenerative diseases like Alzheimer's and Parkinson's.
Researchers from Scripps Research and MIT have discovered a class of extremely potent anti-cancer and anti-neurodegenerative disorder compounds. These compounds, including ABL127, were found using high-throughput screening and innovative testing techniques, and show promise for treating cancer and Alzheimer's disease.
Scientists from Rockefeller University have discovered a new compound, SMER28, which stimulates autophagy and effectively slows down the accumulation of beta-amyloid protein aggregates in rat and mice cells. This approach offers a radically different method to treat Alzheimer's disease and other degenerative diseases.
Researchers at Georgetown University Medical Center have developed a gene therapy that clears toxic proteins from brain cells, preventing plaque formation and neuronal death. The treatment, which is given just once, has been shown to reduce amyloid beta plaque by 75% in mice.
Researchers at Northwestern University have successfully reprogrammed human embryonic stem cells to produce critical neurons lost in Alzheimer's disease. This breakthrough allows for rapid drug testing and the possibility of transplanting these new neurons into people with Alzheimer's, which could help preserve memory function.
The study found three genes that protect mice from brain amyloid accumulation, with lower expression in the liver protecting the mouse brain. One gene encodes Presenilin, a protein contributing to human Alzheimer's, which is expressed in the liver but not the brain.
Researchers at Tel Aviv University develop a 2-in-1 vaccine that repairs vascular damage in the brain, protecting against both Alzheimer's and stroke. The vaccine activates macrophages to clear away damaging amyloid proteins, preventing further damage and promoting repair.
Researchers at University of Michigan have created a new coating that traps and transports molecules through nanopores, enabling the study of single biomolecules with unprecedented precision. This breakthrough technology has significant implications for understanding neurodegenerative diseases like Alzheimer's.
A new study found that individuals with a mother who has Alzheimer's disease are twice as likely to experience gray matter shrinkage and have more whole brain atrophy compared to those with a father or no family history. The research suggests that inheriting the disease from one's mother may be a significant risk factor.
A study of Japanese-American men who died at an average age of 87 found that half of those diagnosed with Alzheimer's did not have sufficient brain lesions to support the diagnosis. Other dementia types, such as Lewy body dementia and vascular dementia, were more accurately diagnosed.
Researchers demonstrate that tau-induced memory loss in Alzheimer's mice is reversible after deactivating the toxic tau gene, allowing them to regain learning and remembering abilities. The study also shows that new synapses form in the brains of mice with a deactivated gene.
A recent study published in Human Molecular Genetics found that increasing a brain enzyme called puromycin-sensitive aminopeptidase can remove toxic tau proteins from neurons. This removal restored neuronal density and slowed down disease progression without any adverse effects. The research suggests that elevating this naturally occur...
Researchers emphasize the importance of financial planning for Alzheimer's patients, noting that doctors often fail to address this critical issue. Early guidance on managing finances is essential, allowing caregivers to take over responsibilities and maintaining patient autonomy.
A study of 639 individuals aged 36-90 found a significant association between hearing loss and dementia. The risk of dementia increased among those with moderate or severe hearing loss, particularly in older adults, who experienced nearly one-third more risk due to hearing loss.
Researchers have developed a novel technology to diagnose Alzheimer's disease from blood samples before symptoms appear, identifying two potential biomarkers with 90% accuracy. This breakthrough could lead to earlier intervention and improved outcomes for patients.
Hippocampal sclerosis (HS-AGING) is a serious condition causing cognitive decline and impaired memory in aged persons. Researchers analyzed autopsy data from 1,100 individuals to define HS-AGING as a distinct disease entity.
Researchers have discovered a link between a variation of the BDNF gene and Alzheimer's disease, with those carrying the gene more likely to exhibit thinner temporal lobe structures and disrupted neural connections. This breakthrough study could lead to early identification and intervention for the disease.
A new study couples a complex genetic screening technique in humans with functional validation of results in flies to study human disease. The strategy has the potential to be an effective approach for understanding complex disorders, such as Alzheimer's disease.
Researchers at the University of Texas Health Science Center San Antonio have identified a new molecule that works with amyloid-beta to speed up Alzheimer's disease. This discovery could lead to the development of drugs that disrupt this interaction, potentially blocking or slowing disease onset and progression.
Douglas Rosenberg invests $3.5 million with Buck Institute to develop treatments for Alzheimer's disease based on small molecule screenings that show promise. The goal is to raise $10 million to get the new drug candidates into early clinical trials.
Researchers are calling for a shift in focus towards prevention, but current therapies targeting brain plaques may be less effective in patients already experiencing symptoms. Developing biomarkers to identify pre-symptomatic volunteers could help test Alzheimer's drugs more effectively.
USF researchers identified CD45 as a critical component in dampening harmful inflammation in the brain's immune response. The study found that a loss of CD45 led to increased microglial inflammation and neurotoxin accumulation in Alzheimer's mouse models.
Researchers at University of Kentucky Sanders-Brown Center on Aging are developing a treatment for Alzheimer's disease by targeting the protein kinase p38alphaMAPK. Their goal is to suppress overactive production of pro-inflammatory cytokines, which disrupt brain function in people with Alzheimer's.
A Wayne State University study successfully classified over three-quarters of healthy older adults at risk for cognitive decline within 18 months. The combination of a genetic blood test and a five-minute functional MRI proved to be the most effective predictor.
Research confirms adult ADHD significantly increases risk of developing degenerative dementia with Lewy bodies (DLB), a common cause of dementia in older adults. The study, published in the European Journal of Neurology, found 48% of patients with DLB had previously suffered from adult ADHD.
Researchers found that presenilin helps guide embryonic motor neurons through a maze of chemical cues, ensuring they reach their targets. Without it, motor neurons misread guidance signals and get stuck in the spinal cord.
Researchers develop molecular imaging procedure to detect beta-amyloid in brains of individuals with Alzheimer's disease, increasing clinical diagnosis accuracy. The study shows a correlation between florbetapir-PET images and presence and quantity of beta-amyloid pathology at autopsy.
Researchers tested how brain network integrity relates to future cognitive decline in people with mild memory problems. They found altered patterns of brain activity in the default mode network among those who later progress to Alzheimer's disease compared to those whose memory remains intact.
Advancements in understanding rotational motion in living cells may shed light on disease causes, such as Alzheimer's. Researchers have developed a new technique using gold nanorods and differential interference contrast microscopy to reveal nanoparticle movement in live cells.
Researchers at UBC-VCH have discovered that excess production of RCAN1 protein sets off a chain reaction killing brain cells in people with Down Syndrome and Alzheimer's Disease. This finding provides a potential new target for drugs to prevent dementia in both populations.
A BRNI study reveals underlying causes of Alzheimer's degeneration and identifies promising pharmaceutical solutions by normalizing the Alzheimer's brain. Treatments that target synapse growth and preservation have shown to prevent disease progression, shifting focus from amyloid plaques.
Alzheimer's disease researchers found that deadly plaques interact with cellular proteins to reduce blood flow and signal molecules in the brain. The study suggests that blocking specific interactions could slow neuronal degeneration and protect nitric oxide production.
A national survey found that 76% of people would take a predictive test to learn about their future health risks, with willingness to pay varying by disease type and accuracy. Respondents were more likely to pay for tests related to breast and prostate cancer, and were willing to alter lifestyle choices after receiving positive results.
Researchers have created a potential method for detecting Alzheimer's disease with a simple blood test using synthetic molecules. The new technology may lead to blood tests for many important diseases if it proves successful.
A study published in Cortex found that the first elements of semantic memory to deteriorate are distinguishing characteristics of a concept, such as a zebra's stripes. This blurs related concepts, leading to temporary improvements in recognizing related words in early Alzheimer's disease.
A study using functional MRI scans found that individuals with the APOE4 gene variant exhibit abnormal brain function before forming senile plaques characteristic of Alzheimer's. Researchers aim to identify high-risk patients and develop treatments to slow disease progression.
Researchers at IRB Barcelona discovered 200 new protein interactions that could be linked to Alzheimer's disease, bringing the total number of interactions to 6000. The study reveals new molecular mechanisms, including oxidative stress and inflammation, which may play a role in the development of the disease.
A Swedish case study reveals how Alzheimer's disease progresses, with high amyloid plaque levels at early stages and declining brain energy. The discovery sheds light on the role of nicotinic receptors and neuroinflammation in the disease, offering new insights for diagnosis and treatment.
A study of 1,130 older adults found that high levels of 'good' cholesterol (HDL) were associated with a decreased risk of both probable and possible Alzheimer's disease. Higher plasma HDL cholesterol was also linked to lower risks despite other factors.
Researchers at UT Health Science Center San Antonio have found that increasing a protein called CBP can restore learning and memory in an Alzheimer's disease mouse model. This breakthrough provides a novel therapeutic target for the development of Alzheimer's medications.
Researchers found that Alzheimer's disease is associated with disrupted brain clearance of a sticky plaque component called amyloid-beta. The study's findings have important implications for diagnosis and treatment, as scientists seek to understand how this process can be improved.